For study purposes, no additional tests were AZD1390 clinical trial performed and it is not standard practice to seek ethical approval for the anonymous

analysis of routine data in Portugal. Results The study population comprises 679 persons working in healthcare with two consecutive QFTs. The study period covers February 2007 until September 2009. Indeterminate results were observed in nine (1.3%) HCWs. One of these nine HCWs had indeterminate results on both occasions. The characteristics of the remaining 670 HCWs as well as of a subgroup of 252 HCWs who had three consecutive QFTs are given in Table 1. The subgroup is comparable to the whole group with respect to the distribution of age, gender, BCG history, profession, risk assessment, and number of TSTs during the study period. Table 1 Description of the study population with two consecutive QFTs and subpopulation with three consecutive QFTs   Two QFTs Three QFTs N % N % Age  16–29 269 40.1 95 37.7  30–39 Cilengitide supplier 175 26.1 68 27.0  40–49 115 17.2 49 19.4  50–59 92 13.7 34 13.5  ≥60 19 2.8 6 2.4 Gender  Female 495 73.9 188 74.6  Male 175 26.1 64 25.4 BCG history  Only at birth

182 27.2 59 23.4  One additional 244 36.4 106 42.1  Two additional 177 26.4 54 21.4  ≥3 additional 67 10.0 33 13.1 TB in history  Yes 79 11.8 28 11.1  No 591 88.2 224 88.9 Profession  Administrators 98 14.6 38 15.1  Auxiliaries, cleaning staff 108 16.1 49 19.4  Technicians (radiology, lab, etc.) 45 6.7 21 8.3  Nurses 307 45.8 110 43.7  Doctors 112 16.7 34 13.5 Risk assessment  Low 94 14.0 48 19.0  Moderate 246 36.7 80 31.8  High 330 49.3 124 49.2 Years working in hospital  <5 283 42.2 101 40.1  5 ≤ 10

115 17.2 44 17.5  10 ≤ 15 84 12.5 33 13.1  15 ≤ 20 58 8.7 27 10.7  ≥20 130 19.4 47 18.7 TST history in last 3 years Dapagliflozin  No TST, old, TST ≥15 mm 138 20.6 46 18.3  One TST 346 51.6 143 56.7  Two TSTs 150 22.4 52 20.6  Three TSTs 36 5.4 11 4.4  Total 670 100.0 252 100.0 The first and second QFTs were positive in 30.0% of the HCWs (Table 2). A conversion occurred in 11.0% of those Smoothened Agonist in vivo negative in the first QFT and a reversion in 22.1% of those positive in the first QFT, if a simple dichotomous approach (negative-positive and vice versa) was chosen. Reversion and conversion rates depended on the INF-γ concentration of the first QFTs. Conversion occurred in 4.8% of the 376 HCWs with an INF-γ concentration at baseline below 0.1 IU/mL but in 48.9% of the 41 HCWs with an INF-γ concentration of 0.2 to <0.35 IU/mL. The same pattern is observed for reversions. In the 49 HCWs with a baseline INF-γ concentration >7.0 IU/mL, two reversions (4.1%) occurred while in those 55 (34 + 21) HCWs with a baseline INF-γ concentration ≥0.35 to <0.7 IU/mL, about every second HCW showed a reversion.